# Yatiri Bio Inc.

> Yatiri Bio is a San Diego biotech using high-resolution mass spectrometry and deep learning to read 8,000-plus proteins per sample, then turn that data into tools pharma companies use to pick the right patients, spot resistance early, and stop burning money on drugs that were never going to work. Founded in 2020 by biophysicist Pilgrim Jackson after 13 years at Celgene, the company sells proteomics-as-insight to drug developers - and in 2025 it landed a Gates Foundation grant and bought its first company.

- **Founded:** 2020
- **Headquarters:** San Diego, California, United States
- **Founders:** Pilgrim Jackson (CEO / Co-Founder), Afshin Mahmoudi (Co-Founder)
- **Team size:** ~14 employees
- **Products:** ProteoBrowser, ProteoModels, ProteoPathway, Discovery Proteomics, Efficacy Models
- **Notable:** Received a Gates Foundation grant (Nov 2025) to advance proteomics interoperability in cancer research., Closed its first acquisition - NGeneBioAI - in Aug 2025, adding CLIA/CAP-certified diagnostics capability., Built a proteomics workflow quantifying 8,000+ proteins per sample.

## Products & services

- **ProteoBrowser** — A fully interactive data portal for exploring proteomics datasets - differential expression, pathway enrichment, outlier testing, and metadata associations - customized per experiment through collaborative iteration with partners.
- **ProteoModels** — A portfolio of patient-derived cellular models matched to molecularly defined cancer subtypes, backed by clinical proteome data. Used for patient-selection optimization, combination-therapy exploration, drug repurposing, and resistance-mechanism discovery.
- **ProteoPathway** — An interactive data portal built on proprietary computational tools that applies machine learning - unsupervised clustering and dimensionality reduction - to explore proteomics data in the context of human biology and signaling pathways.
- **Discovery Proteomics** — Unbiased, high-resolution mass spectrometry service identifying and quantifying 8,000+ proteins per sample, including post-translational modifications, to surface actionable biomarkers.
- **Efficacy Models** — Molecularly tailored preclinical models that improve the correlation between lab systems and the patients they represent, aimed at reducing late-stage clinical failure.

## Achievements

- Received a Gates Foundation grant (Nov 2025) to advance proteomics interoperability in cancer research.
- Closed its first acquisition - NGeneBioAI - in Aug 2025, adding CLIA/CAP-certified diagnostics capability.
- Built a proteomics workflow quantifying 8,000+ proteins per sample.
- Assembled an advisory board spanning the Broad Institute, UC San Diego and Cedars-Sinai.
- Reached ~$8.7M in reported funding as an early-stage, self-directed biotech.

## Latest updates

- **2025-11** — Announced a Gates Foundation grant for the one-year Proteomics Interoperability project targeting HPV-related cervical cancer across three proteomics platforms.
- **2025-08** — Acquired San Diego-based NGeneBioAI, gaining plasma proteomics IP and a CLIA/CAP-certified laboratory for developing laboratory-developed tests (LDTs).
- **2024-04** — Reported $7.0M debt financing, bringing total funding to roughly $8.7M.

## Links

- Website: https://yatiribio.com
- LinkedIn: https://www.linkedin.com/company/yatiri-bio-inc

---

Profile page: https://yespress.io/yatiri-bio-inc
Published by YesPress — https://yespress.io
Last updated: 2026-08-19